Mr. Naufa Hanif | Drug Discovery | Best Researcher Award

Cancer Chemoprevention Research Center - Indonesia

Professional Profiles:

Early Academic Pursuits

Naufa Hanif embarked on his scientific journey with a deep-rooted passion for understanding the intricacies of pharmaceutical chemistry. Completing his master’s degree at the Graduate School of Health Sciences, Faculty of Pharmacy, Hacettepe University in Türkiye, Naufa honed his expertise in computational chemistry, a field where he would make significant strides. His thesis, a pivotal moment in his academic career, revolved around identifying novel drug candidates targeting Indoleamine 2,3-dioxygenase (IDO1) in their apo forms. This research laid the groundwork for his future explorations into the realms of medicinal chemistry and cancer chemoprevention.

Professional Endeavors

Since joining the Cancer Chemoprevention Research Center (CCRC) at UGM in January 2020, Naufa has dedicated his career to the advancement of pharmaceutical research. With a solid foundation in computational and medicinal chemistry, he has led several projects with a focus on discovering novel therapeutic agents. His proficiency in molecular dynamics (MD) simulations and MM-GBSA analysis, coupled with his experience using software like NAMD and VMD, has propelled forward the field of drug discovery, specifically in identifying apo-IDO1 inhibitors.

Contributions and Research Focus on Drug Discovery

He research articulates a seamless blend of genomics, cheminformatics, and bioinformatics, illustrating the complexity of diseases and the requisite multifaceted approach to drug development. His work on glioblastoma treatment, using the curcumin analog CCA-1.1, published in Scientific Reports, underscores his innovative approach to targeting disease. Naufa's research not only advances the scientific community’s understanding of cancer chemoprevention but also contributes significantly to the pharmaceutical field's quest for new, effective treatments.

Accolades and Recognition

His scientific excellence is recognized through various accolades and his contributions to peer-reviewed journals. With eight publications in SCI and SCIE-indexed journals and a similar count in Scopus, Web of Science, and PubMed indexes, his research has garnered attention worldwide. His h-index and citation index reflect the impact of his work, and the recognition from the Journal of Biomolecular Structure and Dynamics for his article on IDO1/TDO2 dual inhibitors highlights his role in advancing drug discovery methodologies.

Impact and Influence

Beyond his publications, Naufa's role as a peer reviewer for genomics and bioinformatics journals has allowed him to influence the direction of research in his field significantly. His dedication is also evident through his involvement in 14 research projects, showcasing his commitment to fostering advancements in pharmaceutical sciences. His scholarly work, recognized by a citation index of 21 and involvement in over 23 editorial appointments, positions him as a leading figure in his domain.

Legacy and Future Contributions

He legacy is characterized by his unwavering commitment to the pursuit of knowledge and the betterment of human health through scientific innovation. His determination, patience, and desire to impact the pharmaceutical field positively have set a precedent for future scientists. Looking ahead, Naufa aims to delve deeper into drug discovery, particularly focusing on diseases that have eluded cure or effective treatment. His future contributions promise to advance our understanding of medicinal chemistry and computational chemistry's role in developing next-generation therapeutic agents.


Naufa Hanif | Drug Discovery | Best Researcher Award

You May Also Like